RaQualia Pharma

Basic Information

Stock Code
4579
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Aichi Prefecture
Establishment Year
February 2008
Listing Year
July 2011
Official Website
https://www.raqualia.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
GNI Group, Heartsseed, Nexela Pharma, Kids Bio, PeptiDream, SanBio, Helios, RenaScience, QualiPs, Takara Bio, Convano, Freas, Japan Tissue Engineering

Overview

RaQualia Pharma is a drug discovery bio-venture established in 2008 with headquarters in Aichi Prefecture, specializing in pain disorders, leveraging its unique compound intellectual property to advance pharmaceutical research and development as a growing company.

Current Situation

RaQualia Pharma recorded net sales of approximately 2.77 billion yen and net profit of approximately 750 million yen in the fiscal year ended December 2021, achieving a turnaround to profitability. Headquartered in Nagoya City, Aichi Prefecture, the company focuses primarily on drug discovery research and development. It has strengths centered on pain disorders and has successfully launched pharmaceuticals such as K-CAB and veterinary drugs. In 2024, it acquired Phimex Co., Ltd. to expand its business. Following shareholder proposals, the management structure has been refreshed, and efforts to strengthen corporate governance are underway. In industry-academia collaboration, it conducts joint research with Nagoya University and Gifu Pharmaceutical University. Since 2022, it has entered into a capital and business alliance with STAND Therapeutics to deepen innovative drug discovery technologies. In the medium to long term, it is seeking to enrich its pipeline and pursue global expansion for sustainable growth.

Trivia

Interesting Facts

  • Rare drug discovery company established by Pfizer Central Research Lab's EBO
  • Attracting attention as an example where shareholder proposals led by individual investors successfully refreshed management
  • One of the few domestic ventures with abundant compound IP for pain disorders
  • Active in industry-academia collaboration with Nagoya University and Gifu Pharmaceutical University
  • Actively expanding into veterinary pharmaceuticals market for differentiation
  • Strengthened research structure by making subsidiary Temlic 100% owned
  • Achieved Tokyo Stock Exchange Growth listing in a relatively short period since establishment
  • Unusual case with over 85% approval rate for shareholder proposal
  • Has history of listing postponement due to poor market conditions but later succeeded
  • Company name is coined from sun (Ra) and sensory quality (Qualia)
  • Deploys multiple specialty pharmaceutical brands while focusing on R&D
  • Rare pharmaceutical venture based in Nagoya
  • Listed product Galliprant is highly evaluated worldwide as a veterinary pharmaceutical
  • Advancing diversification and technology reinforcement through Phimex acquisition
  • Established pharmacological analysis division within Nagoya University to advance high-level research

Hidden Connections

  • Emerged as a new drug discovery venture following the closure of Pfizer Central Research Lab
  • Extremely rare example in Japanese bio companies where shareholder proposal led to management refresh, influencing the market
  • Holds products for specific pets in veterinary pharmaceuticals, with strong ties to veterinarian networks
  • Collaboration with Nagoya University Institute of Environmental Medicine forms the foundation of its unique drug discovery research structure
  • Contributes to revitalization of medical and research industries in the Chubu region as a locally rooted bio-venture
  • Subsidiary Temlic contributes to efficiency of in-house research and field expansion
  • Phimex acquisition complements anti-inflammatory drug manufacturing technology and diversifies drug discovery pipeline
  • Increased corporate information disclosure and improved transparency backed by strengthened accountability to shareholders

Future Outlook

Growth Drivers

  • Expanding demand for pharmaceutical development centered on pain areas
  • Sustainable growth in veterinary pharmaceuticals market
  • Improved drug discovery efficiency through industry-academia collaboration and technology partnerships
  • Enhanced corporate competitiveness through management refresh
  • Overseas market development and increased licensing revenue
  • R&D efficiency improvement through AI and IT technology adoption
  • Revenue diversification through expanded IP utilization
  • Following trends in innovative new drug development in the pharmaceutical industry
  • Improved funding environment accompanying strengthened communication with investors
  • Brand building in veterinary pharmaceuticals field
  • Expansion of regional research collaboration network
  • Flexible business strategies adapting to legal and regulatory changes

Strategic Goals

  • Launch 5 or more drug discovery pipeline products to market
  • Achieve over 30% overseas sales ratio
  • Grow veterinary pharmaceuticals business to domestic top class
  • Expand industry-academia collaboration research and technology development bases
  • Establish sustainable management structure and high corporate governance
  • Achieve annual net sales exceeding 10 billion yen
  • Increase number of new compound patents
  • Revolutionize research processes through digital technology utilization
  • Maintain good relationships with investors and stakeholders
  • Improve Environment, Social, and Governance (ESG) metrics

Business Segments

Drug Discovery Research Support

Overview
Provides compounds and technologies as the foundation for drug discovery, mainly in the pain field, and promotes joint research.
Competitiveness
Technology inheritance from former Pfizer researchers
Customers
  • Pharmaceutical Companies
  • University Research Institutions
  • Biotechnology Companies
  • Academia
Products
  • Compound Libraries
  • Intellectual Property Licensing
  • Contract Research Services

Veterinary Pharmaceuticals Sales and Licensing

Overview
Business expansion through manufacturing, sales, and licensing contracts for pet pharmaceuticals.
Competitiveness
Optimal deployment in domestic and international veterinary markets
Customers
  • Veterinary Hospitals
  • Veterinarians
  • Pet Care Companies
Products
  • Galliprant
  • Entyce
  • Elura

Industry-Academia Collaborative Research

Overview
Innovative pharmaceutical creation through joint research with Nagoya University and Gifu Pharmaceutical University.
Competitiveness
Collaboration with cutting-edge environmental medicine research
Customers
  • Universities
  • Public Research Institutions
  • Pharmaceutical Ventures
Products
  • Industry-Academia Joint Research Programs
  • New Technology Development
  • Pharmacological Analysis

Business Collaboration with Subsidiaries

Overview
Supports a wide range of pharmaceutical development in collaboration with subsidiaries such as Temlic Co., Ltd.
Competitiveness
Synergy effects within the group
Customers
  • Group Companies
  • Contracting Companies
Products
  • Technology Provision
  • Research and Development Support
  • IP Management

Competitive Advantage

Strengths

  • Specialized expertise in drug discovery for pain disorders
  • Drug discovery capabilities inherited from Pfizer
  • Ownership of proprietary compounds and IP
  • Strengthened research and development through industry-academia collaboration
  • Rapid decision-making due to flexible management structure
  • Funding capabilities from Tokyo Stock Exchange Growth listing
  • Business diversification through collaboration with subsidiaries
  • Regionally rooted research base (Nagoya)
  • Expansion into veterinary pharmaceuticals
  • Customer-focused contract research services
  • Solid financial foundation and achievement of profitability
  • Governance strengthening through management refresh
  • Room for improvement in shareholder return policies
  • Development structure centered on technical experts
  • Potential for international partnerships

Competitive Advantages

  • Research know-how specialized in pain-related disorders has high rarity in the market
  • Retention of advanced technology assets and talent independent from Pfizer
  • Broad licensing deployment possible based on abundant compound IP
  • Accelerated new drug development through strong industry-academia collaboration with Nagoya University etc.
  • Diversified revenue base through multifaceted approach to veterinary pharmaceuticals market
  • Achieved higher transparency and rapid response through management structure refresh
  • Improved research efficiency with focused investment strategy in specific areas
  • Growth strategy adapted to funding environment on Tokyo Stock Exchange Growth market
  • Strength in talent development and R&D leveraging regional research bases
  • Preparations underway for FDA and overseas regulatory approvals
  • Vertical integration of research, development, and sales possible through subsidiaries
  • Possesses stable management foundation among emerging bio-ventures
  • Management refresh via individual shareholder proposal as part of governance strengthening
  • Risk diversification through diverse pipeline portfolio
  • Expected market exclusivity for key patented compounds

Threats

  • Risk of market share decline due to intensifying competition with major pharmaceutical companies
  • Uncertainty in new drug approvals in research and development
  • Constraints on growth pace due to changes in funding environment
  • Regulatory tightening and downward pressure on pharmaceutical prices
  • Development and market launch of similar compounds by competitors
  • Obsolescence of research methods due to emerging technologies
  • Possibility of recurrence of corporate governance issues
  • Sales instability due to fluctuations in domestic and international pharmaceutical demand
  • Intensifying competition and regulatory impacts in veterinary pharmaceuticals market
  • Risks of intellectual property infringement and patent disputes
  • Risk of outflow of key research personnel
  • Impact on business activities from disasters or pandemics

Innovations

2024: Business Strengthening through Phimex Acquisition

Overview
Made Phimex a subsidiary to expand technology and product lineup in drug discovery areas.
Impact
Contributes to strengthening R&D capabilities and diversifying sales base

2022: Capital and Business Alliance with STAND Therapeutics

Overview
Promotes joint development of innovative drug discovery platforms and functional compounds.
Impact
Expands new drug candidate pipeline

2021: Management Refresh via Shareholder Proposal

Overview
Aims to improve corporate governance and enhance transparency in management structure.
Impact
Achieves operating profit and sustainable management

2020: Expansion of Intellectual Property Licensing for Pain Compounds

Overview
Concluded licensing agreements for patented compounds with domestic and international companies.
Impact
Increases royalty income and strengthens financial base

2024: Strengthening of Cutting-Edge Environmental Medicine Research Division

Overview
Advances new drug discovery technologies through strengthened collaboration with Nagoya University's pharmacological analysis division.
Impact
Rapid reflection of research outcomes into drug development

2023: Expansion of Veterinary Pharmaceuticals Market Deployment

Overview
Expanded sales channels for Galliprant etc., developing domestic and international veterinary markets.
Impact
Contributes to sales growth and revenue stabilization

2022: New Drug Target Exploration Using AI

Overview
Introduced AI-based compound screening technology.
Impact
Improves research efficiency and speed of drug candidate exploration

Sustainability

  • Establishment of sustainable R&D structure
  • Joint environmental conservation activities with local research institutions
  • Promotion of employee health and safety
  • Maintenance of transparent corporate governance
  • Management aimed at long-term financial soundness
  • Measures to reduce environmental impact of research facilities
  • Thorough ethical animal testing
  • Diversity-respecting talent recruitment policy
  • Job creation through collaboration with local communities
  • Environmentally considerate material procurement